Stocks to buy

Editor’s Note: This column is part of InvestorPlace.com’s Best Stocks for 2021 contest. Eric Fry’s pick for the contest is Osisko Gold Royalties (NYSE:OR). Source: Shutterstock Since our last update in mid-July, Osisko Gold Royalties (NYSE:OR) has continued to deliver relatively forgettable returns for 2021. The stock is down 7% year-to-date, matching gold’s 7% retreat year-to-date. In other
0 Comments
I’ve been pounding the table in support of Lucid Group (NASDAQ:LCID) for a while, but by and large, my pleas have gone unheard. Lately, the price action of LCID stock has been uninspiring. Source: ggTravelDiary / Shutterstock.com Without a doubt, Lucid’s electric vehicles won’t be the cheapest on the market. They’re really only targeted toward folks
0 Comments
The macro picture looks extraordinarily bright for electric vehicle charging infrastructure company ChargePoint (NYSE:CHPT), even if some of the sheen has been taken off CHPT stock this year. Source: David Tonelson / Shutterstock.com The company’s strong second-quarter earnings report was largely overlooked. After an initial post-earnings pop, CHPT stock is down more than 10% since
0 Comments
They call it FUD: fear, uncertainty and doubt. Based in China, ride-hailing giant Didi Global (NYSE:DIDI) has its fair share of problems, I’ll admit. But there’s also plenty of FUD surrounding DIDI stock. Source: Piotr Swat / Shutterstock.com For example, reports recently circulated claiming that China’s Beijing city government advised state-owned companies to invest in the
0 Comments
ViacomCBS (NASDAQ:VIAC) has been a costly disappointment for some investors in 2021. Enthusiasm over the company’s newly-announced streaming plans paired with Reddit-fueled retail investors drove VIAC stock past $100 three weeks into March. That was a 174% gain in under four months. Source: Jer123 / Shutterstock.com A catastrophic crash then saw shares lose half their
0 Comments
Here’s a rare opportunity for you. A “next-generation Medicare Advantage insurer,” Clover Health (NASDAQ:CLOV) operates in a high-potential market, providing health care access to seniors and other patient demographics. Yet, CLOV stock is trading at a surprisingly low price. Source: Shutterstock Currently, this stock has landed gently at a strong support level. So, it might be
0 Comments
The market has experienced increased volatility over the last few weeks. Investors are still nervous about COVID and inflation, plus new issues including the debt ceiling debate and a possibility of an Evergrande default in China. At times like these, investors may look to lower their risk profile.  One way to do that is to
0 Comments
The coronavirus pandemic disrupted many businesses and was a boon to others. One sector that’s been riding high is the pharmaceutical industry. That’s especially true for companies that have brought a Covid-19 vaccine to market. Vaccine developer Novavax (NASDAQ:NVAX) is a perfect example. NVAX stock rose from relative obscurity with a share price of just
0 Comments